The aryl hydrocarbon receptor is a novel negative regulator of interleukin-17-mediated signaling and inflammation in vitro

FEBS Lett. 2019 May;593(9):952-961. doi: 10.1002/1873-3468.13380. Epub 2019 Apr 24.

Abstract

Interleukin (IL)-17 plays a critical role in the pathogenesis of inflammation and autoimmune diseases. The aryl hydrocarbon receptor (AHR) is a transcription factor responsible for the elimination of xenobiotic chemicals. However, it remains unknown whether AHR is involved in IL-17 signaling. Here, we demonstrate that knockdown of AHR significantly enhances, while overexpression or activation of AHR inhibits IL-17-induced inflammation in Hela cells. AHR specifically suppresses IL-17-induced p38 activation, and inhibition of p38 activity markedly reverses the effect of AHR knockdown on IL-17-induced inflammation. Mechanistically, AHR physically interacts with TAK1 and mitogen-activated protein kinase kinase 3/6 (MKK3/6) and disrupts TAK1-MKK3/6 interaction, leading to impaired IL-17 signaling. Thus, our study indicates that AHR negatively regulates IL-17-mediated signaling and inflammation at least partially through interfering with the interaction between TAK1 and MKK3/6.

Keywords: AHR; IL-17; MKK3/6; P38.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • HeLa Cells
  • Humans
  • Inflammation / metabolism
  • Inflammation / pathology
  • Interleukin-17 / metabolism*
  • MAP Kinase Kinase 3 / metabolism
  • MAP Kinase Kinase 6 / metabolism
  • MAP Kinase Kinase Kinases / metabolism
  • MAP Kinase Signaling System
  • Receptors, Aryl Hydrocarbon / metabolism*
  • Signal Transduction*
  • p38 Mitogen-Activated Protein Kinases / metabolism

Substances

  • Interleukin-17
  • Receptors, Aryl Hydrocarbon
  • p38 Mitogen-Activated Protein Kinases
  • MAP Kinase Kinase Kinases
  • MAP kinase kinase kinase 7
  • MAP Kinase Kinase 3
  • MAP Kinase Kinase 6
  • MAP2K6 protein, human